Quarterly report pursuant to sections 13 or 15(d)

Note Payable - Additional Information (Detail)

v2.4.0.8
Note Payable - Additional Information (Detail) (USD $)
 3 Months Ended 12 Months Ended 94 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Sep. 30, 2013
Dec. 31, 2013
Note Payable [Line Items]        
Notes Payable, Total     $ 944,707  
Adjustments to Additional Paid in Capital, Warrant Issued     55,293  
Interest Expense, Total 27,765 42,981   616,361
Warrant
        
Note Payable [Line Items]        
Fair Value Assumptions, Risk Free Interest Rate     2.64%  
Fair Value Assumptions, Expected Dividend Rate     0.00%  
Fair Value Assumptions, Expected Term     10 years  
Fair Value Assumptions, Expected Volatility Rate     114.00%  
Massachusetts Life Sciences Center
        
Note Payable [Line Items]        
Subordinated Debt     $ 1,000,000  
Debt Instrument, Payment Terms     The loan bears interest at a rate of 10% per annum, and will become fully due and payable on the earlier of (i) September 30, 2018, (ii) the occurrence of an event of default under the MLSC Loan Agreement, or (iii) the completion of a sale of substantially all of our assets, a change-of-control transaction or one or more financing transactions in which we receive net proceeds of $5,000,000 or more in a 12-month period.  
Warrants Issued To Purchase Of Common Stock     145,985  
Class Of Warrant Or Right Expiration Date     Sep. 30, 2023